| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 7.3MM | +4% |
| Gross Profit | 3.6MM | -18% |
| Cost Of Revenue | 3.7MM | +40% |
| Operating Income | -2MM | - |
| Operating Expenses | 5.6MM | +14% |
| Net Income | -2.3MM | - |
| R&D | 1MM | +70% |
| G&A | 4.6MM | +6% |
| Amortization | 426.8K | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is expected to be accretive to 2024 earningsEstimated peak sales of more than $10 million annuallyU.S. phenylketonuria ("PKU") medical formula market estimated to be $100 million annually DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company foc
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call Transcript March 14, 2024 Eton Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Eton Pharmaceuticals’ Fourth Quarter 2023 Financial Results Conference Call. At this time, […]
Q4 2023 Eton Pharmaceuticals Inc Earnings Call
ETON Sees Over 100% Year-Over-Year Increase in Q4 Product Sales; Prepares for New Drug Applications
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -125% and 5.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growthFull year 2023 revenues reached $31.6 million with product sales and royalty revenues of $26.1 million, a 132% increase from 2022Announced successful results from ET-400’s pivotal bioequivalence study, NDA submission planned for Q2 2024Management to hold conference call today at 4:30pm ET DEER PARK, Ill., March 14, 2024 (GLOBE NEWSWIRE) -- Eton Pha
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 19.23% and 108%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT). Register* (Audio Only) Click here I
Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.
DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office (“USPTO”) has granted the Company’s U.S. Patent Application No. 18/113,458, which covers the Company’s ET-400 product candidate’s proprietary formulation of oral liquid hydrocortisone. The patent has an expirat